Background: Semaglutide showed an attractive weight loss effect in obese patients with T2D. Additionally, semaglutide significantly helped the to achieve glycemic control and improved lipid profiles. No adverse effects were documented in these studies secondary to semaglutide use. Objectives: To study the effects of semaglutide on body weight in obese individuals with type 2 diabetes (T2D), as well as effects and correlations between weight loss, glycemic control and lipid profile. Methods: We conducted a thorough search of PubMed, SCOPUS, Web of Science, and Science Direct to find pertinent literature. Rayyan QRCI was utilized during the entire process. Results: We included seven studies with a total of 480 T2D patients with obesity and 267 (55.6%) were males. Six of the seven included studies reported a significant decrease in HbA1C, body weight, and LDL among obese T2D patients. Regarding dosages, concurrent drugs, and the length of the intervention, there was a great deal of variation among studies. Several semaglutide dosage schedules were used in the trials that were found. Randomized and cohort studies substantiate semaglutide's better effectiveness over other GLP-1 RAs in helping T2D patients lose weight, achieve glycemic control, and improve lipid profiles. No adverse effects were documented in these studies secondary to semaglutide use. Conclusion: The current data of research was synthesized in this systematic review to investigate how semaglutide affects body weight, glycemic control, and lipid profiles in T2D patients. There is proof that semaglutide, a dual mechanism GLP-1/GIP RA, is superior to comparator GLP-1 RAs in terms of weight loss, glycemic control, and improving lipid profiles.